A Double-blind, Randomized, Controlled, Phase IIb Field Trial in 12 to 47 Month-old Children in Western Kenya to Evaluate the Efficacy, Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine (WRAIR's MSP-1 Antigen Adjuvanted in GlaxoSmithKline's AS02A) Versus Rabies Vaccine